Page 28 - DIAGEN-EN

Hematology primeFISH Products

HEMATOLOGY
PANEL

17-133 MLL-MLLT3 t(9;11)

The KMT2A (MLL) gene located at 11q23 is rearranged in protein complexes. It has been identified to have over 80
the majority of acute lymphoblastic leukemia (ALL) or acute fusion partners. The most common translocation partners
myeloid leukemia (AML) patients, and in approximately in KMT2A-associated leukemia are AFF1, MLLT3, MLLT1,
10% of all acute leukemia patients. In infants, the incidence MLLT10, ELL, and AFDN (MLLT4), respectively. KMT2A is
of KMT2A rearrangements is around 70-80%. KMT2A is involved in approximately 3-5% of adult de novo AML
a nuclear protein with methyltransferase activity and is cases, and the most common deviation in this subgroup
involved in the regulation of target genes necessary for is the t(9;11)(p22;q23) involving the MLLT3 gene.
early development and hematopoiesis as part of multiple

TRANSLOCATION

9p21.3

SHGC-155125 SHGC-106080
3' 5'
Tel Cent
MLLT3
811 kb NORMAL

WI-9069 D11S797
5' 3'
Cent Tel
KMT2A
TRANSLOCATION
485 kb

11q23.3

(Not to scale)

www.diagen.com.tr References
Cavazzini et al (2006) Haematologica 91:381-385
Winters and Bernt (2017) Front. Pediatr. 5:4. doi: 10.3389/fped.2017.00004
Barber KE, et al. Genes Chromosomes Cancer. 41(3):266-71 (2004).
Anguita E, et al. Cancer Genet Cytogenet. 120(2):144-7 (2000).

28 PRODUCT CATALOGUE